CurifyLabs secures $14 million to 3D-print customized medicine.

      Your prescription, customized to order. A Finnish startup aims to transform the back area of your pharmacy into a compact, automated drug manufacturing facility and has recently secured $14 million to implement this in the United States.

      CurifyLabs announced the completion of a €12 million ($14 million) Series A funding round. The Helsinki-based company develops machines and software that enable pharmacies to 3D-print personalized medications on-site. This funding will enable further expansion into the U.S. market, where its technology is already operational in pharmacies across 21 states.

      Tailored medication

      Most medications are available in standard doses. However, children, senior patients, and individuals with rare conditions often require doses that fall in between or entirely different forms. Pharmacists have traditionally prepared these by hand, a time-consuming and error-prone process known as compounding.

      CurifyLabs streamlines this process through automation. Its system combines software with pharmaceutical-grade ingredient bases and a 3D printer to produce customized doses equipped with integrated quality checks.

      The latest model, the PharmaPrinter Aurum, reportedly compounds up to nine times faster than manual methods, according to the company. The technology holds ISO 13485 certification and complies with the U.S. FDA’s regulations for non-sterile compounding.

      A Nordic strategy in the U.S. market

      The funding round was co-led by Sandwater and HealthCap, with participation from Finland’s state investor Tesi and existing investor Lifeline Ventures. Some customers and employees from the U.S. also contributed. The funds will be allocated toward U.S. expansion, supply chain improvements, customer support, and research efforts.

      “Their progress in the U.S. further demonstrates that Finnish health technology can successfully compete on a global scale,” remarked Joni Karsikas of Tesi. This reflects a well-established Nordic aspiration, as Espoo’s IQM recently listed in New York, and the region continues to propel its deep-tech companies across the Atlantic.

      A small round with vast potential

      Founded in 2021 by CEO Charlotta Topelius and pharmaceutical scientist Niklas Sandler, CurifyLabs raised this funding following a €6.7 million round last year. Although the amount is modest compared to a multi-trillion-dollar pharmaceutical market, the automation of its more complex aspects represents a viable business opportunity.

      Others are pursuing similar advancements, from pharmacist-free dispensaries to an influx of European drug-tech investments, alongside significant public precision-medicine initiatives. Personalized medicine has been “in the works” for years, and CurifyLabs is optimistic that, with each printed dose, it is finally about to materialize.